1. Home
  2. ZURA vs TLS Comparison

ZURA vs TLS Comparison

Compare ZURA & TLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zura Bio Limited

ZURA

Zura Bio Limited

N/A

Current Price

$4.14

Market Cap

455.4M

Sector

Health Care

ML Signal

N/A

Logo Telos Corporation

TLS

Telos Corporation

N/A

Current Price

$4.24

Market Cap

358.0M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ZURA
TLS
Founded
2022
1969
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
455.4M
358.0M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
ZURA
TLS
Price
$4.14
$4.24
Analyst Decision
Strong Buy
Buy
Analyst Count
7
6
Target Price
★ $18.00
$6.33
AVG Volume (30 Days)
★ 1.5M
621.2K
Earning Date
11-12-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.51
EPS
N/A
★ 0.03
Revenue
N/A
★ $164,805,000.00
Revenue This Year
N/A
$16.14
Revenue Next Year
N/A
$0.26
P/E Ratio
★ N/A
$135.67
Revenue Growth
N/A
★ 52.21
52 Week Low
$3.15
$3.79
52 Week High
$7.25
$8.36

Technical Indicators

Market Signals
Indicator
ZURA
TLS
Relative Strength Index (RSI) 32.37 46.50
Support Level $3.90 $4.07
Resistance Level $5.87 $4.68
Average True Range (ATR) 0.29 0.14
MACD -0.06 0.00
Stochastic Oscillator 18.75 57.65

Price Performance

Historical Comparison
ZURA
TLS

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

About TLS Telos Corporation

Telos Corp offers technology solutions and services that empower and protect the world's security-conscious organizations. The company delivers efficient, adaptable, and secure solutions that protect people, organizations, and information across government and industry. The company conducts its business through two reportable and operating segments: Security Solutions and Secure Networks. The Security Solutions segment is focused on cybersecurity, cloud, and identity solutions, and secure messaging through Xacta, Telos AMHS, and Telos ID offerings. The Secure Networks segment provides secure networking architectures and solutions to customers through secure mobility solutions, network management, and defense services. The majority of revenue is from Secure Networks.

Share on Social Networks: